An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors

Published:2019-05-14 Issue:2 Volume:28 Page:561-570
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

O’Reilly Aine,Hughes Peta,Mann Jasmine,Lai Zhuangming,Teh Jhia Jiat,Mclean Emma,Edmonds Kim,Lingard Karla,Chauhan Dharmisha,Lynch Joanna,Au Lewis,Ludlow Aileen,Pattison Natalie,Wiseman Theresa,Turajlic Samra,Gore Martin,Larkin James,Husson Olga

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-019-04818-w.pdf

Reference34 articles.

1. Mayer DK, Nasso SF, Earp JA (2017) Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA. Lancet Oncol 18(1):e11–e18. https://doi.org/10.1016/S1470-2045(16)30573-3

2. Jacobs LA, Shulman LN (2017) Follow-up care of cancer survivors: challenges and solutions. The Lancet Oncology 18(1):e19–e29. https://doi.org/10.1016/S1470-2045(16)30386-2

3. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119–iv142. https://doi.org/10.1093/annonc/mdx225

4. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J ImmunoTher Cancer 5(1):95. https://doi.org/10.1186/s40425-017-0300-z

5. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168. https://doi.org/10.1056/NEJMra1703481

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients’ Quality of Life and the Role of Dermatologic Intervention;Dermatology Practical & Conceptual;2024-07-31

2. From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting;BMC Cancer;2024-05-30

3. Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study;Supportive Care in Cancer;2024-05-06

4. The psychological distress of gastrointestinal cancer patients and its association with quality of life among different genders;Supportive Care in Cancer;2024-05-06

5. Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study;Cancers;2024-04-24